Gilead Sciences

$74.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.17 (-1.54%) Today
-$0.30 (-0.40%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!

About GILD

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Employees
11,800
Headquarters
Foster City, California
Founded
1987
Market Cap
92.06B
Price-Earnings Ratio
17.27
Dividend Yield
3.73
Average Volume
28.74M
High Today
$76.33
Low Today
$73.79
Open Price
$75.90
Volume
12.12M
52 Week High
$85.97
52 Week Low
$60.89

Collections

GILD News

ReutersMar 30

BRIEF-Gilead Announces Expiration Of Hart-Scott-Rodino Waiting Period For Forty Seven Tender Offer

March 30 (Reuters) - Gilead Sciences Inc: * GILEAD ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR FORTY SEVEN TENDER OFFER * GILEAD SCIENCES INC
437
CNBCMar 26

Gilead pauses access to experimental COVID-19 drug due to 'overwhelming demand'

A close up of a test kit for testing for the coronavirus, Covid-19 is seen at Newton-Wellesley Hospital in Newton, Massachusetts on March 18, 2020, as the hospi
780
CNBCMar 26

CEO of largest NY health provider: Only science can dictate coronavirus drug treatments

Northwell Health CEO Michael Dowling on Thursday called for caution regarding potential drug treatments for COVID-19. "You can't let politics dictate, what peo
106

GILD Earnings

$0.00
$0.61
$1.23
$1.84
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
per share
Actual
Expected Apr 30, After Hours

People Also Bought

You May Also Like

More GILD News

Financial TimesMar 26

The global hunt for a coronavirus drug | Free to read

It was Friday March 13 when doctors at Northwell Health, the largest healthcare provider in New York City, decided to take the search for a coronavirus drug int
44
New York TimesMar 25

Gilead Asks FDA to Take Back Lucrative Orphan Drug Status on Possible Coronavirus Treatment

(Reuters) - Gilead Sciences Inc on Wednesday took the unusual step of asking the U.S. Food and Drug Administration to rescind a controversial orphan drug design
519
ReutersMar 25

Gilead asks FDA to revoke orphan drug status for potential coronavirus drug

March 25 (Reuters) - Gilead Sciences Inc said on Wednesday it had requested the U.S. Food and Drug administration to rescind the “orphan drug” status for its ex
138
ReutersMar 25

BRIEF-Gilead Says Submitted Request To FDA To Waive All Benefits That Accompany Orphan Drug Designation

March 25 (Reuters) - Gilead Sciences Inc: * GILEAD SCIENCES SAYS SUBMITTED REQUEST TO U.S. FDA TO RESCIND ORPHAN DRUG DESIGNATION GRANTED FOR INVESTIGATIONAL A
49
ReutersMar 25

BRIEF-Gilead requests FDA pull orphan drug designation from potential coronavirus drug

March 25 (Reuters) - Gilead Sciences Inc: * Says requested the U.S. FDA rescind the orphan drug designation it was granted for potential coronavirus drug remde
20
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.